Barnett S. Kramer
#166,909
Most Influential Person Now
Barnett S. Kramer's AcademicInfluence.com Rankings
Barnett S. Kramermedical Degrees
Medical
#3451
World Rank
#3919
Historical Rank
Public Health
#539
World Rank
#556
Historical Rank
Barnett S. Kramerphilosophy Degrees
Philosophy
#9866
World Rank
#13483
Historical Rank
Logic
#6821
World Rank
#8371
Historical Rank
Download Badge
Medical Philosophy
Barnett S. Kramer's Degrees
- Masters Public Health Johns Hopkins University
Why Is Barnett S. Kramer Influential?
(Suggest an Edit or Addition)Barnett S. Kramer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mortality results from a randomized prostate-cancer screening trial. (2009) (2824)
- Design and endpoints of clinical trials in hepatocellular carcinoma. (2008) (1216)
- Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. (2012) (1053)
- The National Lung Screening Trial: overview and study design. (2011) (1043)
- Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. (2011) (942)
- Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. (2012) (883)
- The role of increasing detection in the rising incidence of prostate cancer. (1995) (695)
- Overdiagnosis in low-dose computed tomography screening for lung cancer. (2014) (644)
- Ovarian cancer: screening, treatment, and followup. (1995) (579)
- The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. (2000) (498)
- Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. (2016) (446)
- Potential role of tamoxifen in prevention of breast cancer. (1991) (384)
- Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. (2011) (382)
- Trends in biomarker research for cancer detection. (2001) (367)
- Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. (1987) (332)
- Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. (2005) (305)
- Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
- Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (277)
- Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. (1994) (240)
- The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology (2013) (226)
- Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. (1987) (214)
- Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. (1994) (205)
- Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. (2007) (201)
- Principles of cancer screening: lessons from history and study design issues. (2010) (186)
- Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. (2005) (174)
- Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years (2017) (166)
- American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. (2010) (165)
- Trends and black/white differences in treatment for nonmetastatic prostate cancer. (1998) (165)
- Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial (2008) (161)
- Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. (1983) (157)
- Cancer overdiagnosis: a biological challenge and clinical dilemma (2019) (154)
- Design of the Prostate Cancer Prevention Trial (PCPT). (1995) (150)
- A perfect correlate does not a surrogate make (2003) (149)
- Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. (2015) (147)
- Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST) (2011) (139)
- Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. (2016) (138)
- Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (2010) (132)
- A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers (2010) (131)
- Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening (2009) (129)
- Cancer screening in theory and in practice. (2005) (129)
- A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. (1991) (127)
- Using relative utility curves to evaluate risk prediction (2009) (125)
- The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States (1998) (124)
- Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (119)
- Transforming Epidemiology for 21st Century Medicine and Public Health (2013) (116)
- National Institutes of Health Consensus Development Conference Statement on Cervical Cancer (1997) (114)
- A population approach to precision medicine. (2012) (113)
- Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2009) (113)
- Tobacco addiction: implications for treatment and cancer prevention. (1997) (112)
- Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2006) (108)
- New Models for Large Prospective Studies: Is There a Better Way? (2012) (107)
- Markers for early detection of cancer: Statistical guidelines for nested case-control studies (2002) (104)
- American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. (2009) (103)
- Prostate Cancer Screening - A Perspective on the Current State of the Evidence. (2017) (102)
- Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study (1992) (99)
- Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. (2016) (98)
- Epidemiologic Signatures in Cancer. (2019) (97)
- Cancer screening campaigns--getting past uninformative persuasion. (2012) (96)
- National Lung Screening Trial Findings by Age: Medicare-Eligible Versus Under-65 Population (2014) (94)
- The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? (2002) (93)
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. (2009) (86)
- Population-based screening for cancer: hope and hype (2016) (86)
- Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. (2005) (85)
- Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). (1989) (85)
- Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. (1982) (84)
- Paradoxes in carcinogenesis: New opportunities for research directions (2007) (82)
- Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
- Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. (1988) (77)
- Cancer screening: the clash of science and intuition. (2009) (77)
- Conceptualizing overdiagnosis in cancer screening. (2015) (76)
- 5-Alpha-reductase inhibition and prostate cancer prevention. (1994) (74)
- Peirce, Youden, and Receiver Operating Characteristic Curves (2007) (74)
- The management of primary lymphoma of bone. (1987) (73)
- The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute (1995) (71)
- Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. (2003) (71)
- Evaluating markers for the early detection of cancer: overview of study designs and methods (2006) (69)
- Cumulative Incidence of False-Positive Test Results in Lung Cancer Screening (2010) (68)
- Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. (2007) (68)
- Conceptualizing De-Implementation in Cancer Care Delivery. (2019) (61)
- Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. (1985) (61)
- Five-alpha-reductase Inhibitors for prostate cancer prevention. (2008) (61)
- Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. (2006) (60)
- Cutaneous infarction. Manifestation of disseminated mucormycosis. (1977) (59)
- Early Detection Cancer Research Network (2000) (57)
- Identifying genes that contribute most to good classification in microarrays (2006) (57)
- American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. (2009) (56)
- Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients (1986) (54)
- Cancer chemotherapy associated symptomatic stomatitis. Role of herpes simplex virus (HSV) (1982) (53)
- The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. (2013) (52)
- Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (50)
- 5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review (2010) (48)
- Screening for prostate cancer with PSA testing: current status and future directions. (2011) (48)
- Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening. (2015) (48)
- Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology. (2015) (45)
- Variability in flexible sigmoidoscopy performance among examiners in a screening trial. (2005) (44)
- Statistical issues in randomized trials of cancer screening (2002) (43)
- Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies. (2001) (43)
- Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines. (1990) (41)
- Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients. (1983) (41)
- A common standard for conflict of interest disclosure in addiction journals. (2009) (41)
- Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial (2007) (36)
- Biomarkers, subgroup evaluation, and clinical trial design. (2012) (35)
- Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats (2009) (34)
- The science of early detection. (2004) (33)
- The Paired Availability Design for Historical Controls (2001) (33)
- Lung cancer risk by years since quitting in 30+ pack year smokers (2015) (32)
- Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis (2005) (32)
- Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. (1985) (31)
- Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. (1986) (31)
- Promoting healthy skepticism in the news: helping journalists get it right. (2009) (29)
- Lead time and overdiagnosis. (2014) (28)
- Getting It Right: Being Smarter about Clinical Trials (2006) (28)
- Analysis of the role of cancer prevention and control measures in reducing cancer mortality. (1991) (28)
- Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. (2006) (28)
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. (2009) (27)
- Chemoprevention (1995) (27)
- Relationship of demographic and clinical factors to free and total prostate-specific antigen. (2001) (27)
- Latent class instrumental variables: a clinical and biostatistical perspective (2016) (26)
- AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
- Grappling with cancer--defeatism versus the reality of progress. (1997) (26)
- Surrogate endpoint analysis: an exercise in extrapolation. (2013) (26)
- Estimating the cumulative risk of false positive cancer screenings (2003) (26)
- Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. (1986) (26)
- The randomized registry trial. (2014) (25)
- Estimating the Cumulative Risk of a False‐Positive Test in a Repeated Screening Program (2004) (24)
- Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer: A Southeastern Cancer Study Group Trial (1988) (24)
- Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers. (2021) (24)
- Breast cancer screening: toward informed decisions. (2014) (24)
- National Children's Study: update in 2010. (2011) (23)
- Focusing on overdiagnosis as a driver of too much medicine (2018) (23)
- Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. (1993) (23)
- The potential for hormonal prevention trials (1994) (22)
- Evaluation of in vitro chemosensitivity using human lung cancer cell lines (1996) (21)
- Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. (2015) (21)
- Spontaneous regression of testicular seminoma: case report. (1986) (21)
- Induced abortion, bias, and breast cancer: why epidemiology hasn't reached its limit. (1996) (21)
- Cancer prevention and the American Society of Clinical Oncology. (2004) (21)
- Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. (2005) (21)
- Expanding horizons in breast and prostate cancer prevention and early detection. The 1992 Samuel C. Harvey Lecture. (1993) (21)
- Molecular and genetic targets in early detection. (1999) (20)
- Systems biology and cancer: promises and perils. (2011) (20)
- Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience. (1998) (20)
- Cancer Prevention in the United States (2013) (19)
- NIH Consensus 1994: screening. (1994) (19)
- Is screening for prostate cancer the current gold standard?--"no". (1997) (18)
- 5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451)) (2011) (17)
- Projecting the benefits and harms of mammography using statistical models: proof or proofiness? (2015) (17)
- Short course prophylactic cranial irradiation for small cell lung cancer (1985) (17)
- Prophylaxis of fever and infection in adult cancer patients. A placebo‐controlled trial of oral trimethoprim‐sulfamethoxazole plus erythromycin (1984) (16)
- Development Tracks for Cancer Prevention Markers (2004) (15)
- Clinical trial design and evidence-based outcomes in the study of liver diseases. (2009) (15)
- The word “cancer”: how language can corrupt thought (2013) (15)
- Clinical oncology update: Prostate cancer (1997) (14)
- The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results. (2015) (14)
- Short‐Term Outcome Among Patients With Leukemia and Lymphoma Admitted to a Medical Intensive Care Unit (1986) (14)
- Randomized trials, generalizability, and meta-analysis: Graphical insights for binary outcomes (2003) (13)
- Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes (2015) (13)
- Genetics of lung cancer: implications for early detection and prevention. (1995) (13)
- Evaluating a new marker for risk prediction: decision analysis to the rescue. (2012) (13)
- Efficacy of injectable and oral paste formulations of ivermectin against gastrointestinal parasites in ponies. (1982) (12)
- Early reporting for cancer screening trials (2008) (12)
- Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank (2016) (12)
- Cancer Prevention: Lessons Learned and Future Directions. (2016) (11)
- Schedule‐dependent in vitro combination effects of methotrexate and 5‐fluorouracil in human tumor cell lines (1991) (11)
- Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics. (2008) (11)
- "Screening for prostate cancer". (1994) (11)
- Cancer screening. (2021) (11)
- The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications (2017) (11)
- Statistics for weighing benefits and harms in a proposed genetic substudy of a randomized cancer prevention trial (2005) (11)
- Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening (2003) (10)
- Prostate cancer screening: current issues. (1996) (10)
- Enhancement of fluorinated pyrimidine‐induced cytotoxicity by leucovorin in human lung cancer cell lines (1990) (10)
- Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. (1986) (10)
- Screening for prostate cancer: current status and future prospects. (2007) (9)
- Evidence-Based Approach to Oncology (2006) (9)
- Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial. (1984) (9)
- Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests (2008) (9)
- Clarifying the Role of Principal Stratification in the Paired Availability Design (2011) (8)
- Screening for Prostate Cancer with Prostate-Specific Antigen: What's the Evidence? (2012) (8)
- The risky reliance on small surrogate end point studies when planning a large prevention trial (2013) (8)
- Current status of the National Children's Study. (2010) (8)
- Incidental renal tumours on low-dose CT lung cancer screening exams (2017) (8)
- Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial. (2018) (8)
- Estimating overdiagnosis in lung cancer screening--reply. (2014) (7)
- Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs. (2015) (7)
- Overstating the Evidence for Lung Cancer Screening (2007) (7)
- Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. (2010) (7)
- Validation: a critical step in bringing biomarkers to clinical fruition. (2017) (7)
- The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a "free lunch"? (2004) (7)
- An outlier theory of cancer curability. Tumor cell differentiation as a therapeutic goal. (1987) (7)
- Lung Cancer Screening Websites-Balanced Information vs Advertisement. (2020) (6)
- Cancer overdiagnosis: a challenge in the era of screening. (2022) (6)
- Health screening needs independent regular re-evaluation (2021) (6)
- Randomized trials for the real world: making as few and as reasonable assumptions as possible (2008) (6)
- DeImplementing Ineffective and Low-Value Clinical Practices: Research and Practice Opportunities in Community Oncology Settings. (2021) (5)
- Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse Reactions (1985) (5)
- Thrombotic thrombocytopenic purpura associated with metastatic gastric adenocarcinoma: successful management with plasmapheresis. (1986) (5)
- Vasectomy and increased risk of prostate cancer [letter] (1993) (4)
- Abstract 1795: The feasibility study of a randomized cancer screening trial in China (2016) (4)
- Breast Cancer Screening (2014) (4)
- Cancer Prevention: Lessons Learned and Future Directions. (2016) (4)
- Thyroid incidentalomas in association with low-dose computed tomography in the National Lung Screening Trial. (2019) (4)
- Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up. (1985) (4)
- General keynote: cancer screening: translation of principles into practice. (2003) (4)
- Future Directions for Postdoctoral Training in Cancer Prevention: Insights from a Panel of Experts (2014) (4)
- Treatment of Residual Disease in AML: Interim Analysis of a Southeastern Cancer Study Group Prospective Randomized Clinical Trial (1986) (3)
- Screening for Lung Cancer With Helical CT Scanning (2002) (3)
- JNCI and cancer prevention. (2015) (3)
- Study designs for determining and comparing sensitivities of disease screening tests (2015) (3)
- Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. (1994) (3)
- Here's to Your Health (2006) (3)
- Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial. (1986) (3)
- Predictive Value Tools as an Aid in Chemopreventive Agent Development. (2013) (3)
- Matching strength of message to strength of evidence: a discussion. (1999) (3)
- Colorectal cancer prevention and fishful thinking. (2015) (2)
- Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial (2007) (2)
- Editorial: Challenges in Quantifying Overdiagnosis. (2017) (2)
- Dipyridamole mediated enhanced antiproliferative activity of 10‐ethyl‐10‐deazaaminopterin (10‐EDAM) against human lung cancer cell lines (1996) (2)
- Comprehensive Quality Management (CQM) in the PLCO Trial. (2015) (2)
- Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. (1990) (2)
- Overview of U.S. National Cancer Institute (USNCI) chemoprevention research. (1994) (2)
- Spiral computed tomography screening: study begins to determine its efficacy in lung cancer prevention. (2001) (2)
- Multilevel modeling and value of information in clinical trial decision support (2014) (1)
- Phase II Evaluation of Diaziquone in Gastric and Pancreatic Cancers A Southeastern Cancer Study Group Trial (1986) (1)
- Granulocytopenic Cancer Patients (1)
- 16. Diffuse Lymphoma of Bone (1985) (1)
- Overuse and De-Implementation of Inappropriate Cancer Screening, Diagnosis, and Treatment Practices (2018) (1)
- Epidemiologic Signatures in Cancer. Reply. (2020) (1)
- Reply to P.C. Walsh (2009) (1)
- Special Feature — Biostatistics: Why Biotechnologists Should Care about Biostatistics (2006) (1)
- Treatment of refractory acute leukemia with high-dose chemotherapy. (1977) (1)
- NATIONAL CHILDREN'S STUDY: STATUS IN 2010 (2012) (1)
- 333 FAMILY HISTORY OF VARIOUS CANCERS AND THE RISK OF INCIDENT PROSTATE CANCER IN THE PLCO TRIAL (2011) (1)
- SPECIAL ARTICLE Tobacco Addiction: Implications for Treatment and Cancer Prevention (1997) (1)
- Biomedical research and dissemination: The value of global collaborations (2021) (1)
- Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening (2020) (1)
- Phase II evaluation of amsacrine in small cell lung cancer: a Southeastern Cancer Study Group trial. (1985) (1)
- Is screening for prostate cancer the current gold standard : No : Prostate cancer - Part I: Epidemiology and prevention (1997) (1)
- An Outlier Theory of Cancer Curability. Tumor Cell Differentiation as a Therapeutic Goal (1988) (0)
- Re: Sector resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: Five-Year Results of a Randomized Trial (1995) (0)
- Vasectomy and increased risk of prostate cancer. (1993) (0)
- A Commencement for the Journal: the Inspiration of Janus (2002) (0)
- The Mayo Lung Project lung cancer mortality findings are unlikely to be biased by a volunteer effect (2011) (0)
- Abstract B53: Predicting efficacy of chemopreventive agents in animal tumor assays by statistical modeling (2015) (0)
- 14 Incidental detection of thyroid abnormalities on low-dose computed tomography in the national lung screening trial (2018) (0)
- The Increasing Incidence of Early-Onset Colorectal Cancer. (2022) (0)
- Survival patterns as a function of time with solid tumors. (1985) (0)
- Correction to "Latent class instrumental variables: A clinical and biostatistical perspective". (2018) (0)
- Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation. (1984) (0)
- Breast-Cancer Tumor Size and Screening Effectiveness. (2017) (0)
- Challenges in Quantifying Overdiagnosis (2017) (0)
- Screening Theory and Study Design: The Basics (2021) (0)
- Reply to J. Cabezas et al. (2016) (0)
- Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline (2009) (0)
- Abstract P5-11-06: Understanding predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal mammary gland tumor assays (2015) (0)
- Reply to P.H. Frankel et al (2009) (0)
- PROSTATE CANCER SCREENING. AUTHOR'S REPLY (1994) (0)
- In Memoriam: Daniel C. Ihde (2005) (0)
- 222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assays (2014) (0)
- 573 FACTORS INFLUENCING PROSTATE CANCER MORTALITY IN THE PLCO TRIAL (2010) (0)
- Response: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right (2010) (0)
- 376 Aspirin May Reduce the Risk of Gastric, but Not Esophageal Adenocarcinoma: A Prospective Cohort Analysis (2015) (0)
- Cancer overdiagnosis: a biological challenge and clinical dilemma (2019) (0)
- Correction: The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? (2003) (0)
- Spiral computed tomography screening (2000) (0)
- Op-Ed Spiral computed tomography screening (2001) (0)
- Cancer Epidemiology in the 21 st Century Transforming Epidemiology for 21 st Century Medicine and Public Health (2013) (0)
- RACIAL DIFFERENCES IN RADICAL PROSTATECTOMY. AUTHORS' REPLY (1995) (0)
- Chemoprevention : Using Drugs and Nutrients to Decrease Cancer Risk (2016) (0)
- Abstract IA25: Implementation of risk prediction to improve health: The promises and challenges of precision (2017) (0)
- RESEARCH HIGHLIGHTS: EBM from the Cochrane Library (2009) (0)
- Abstract 2813: Chemoprevention of mammary cancer: Modeling predictive values of short-term morphologic assays for efficacy in animal tumor assays (2015) (0)
- Cancer screening: Translation of principles into practice (2003) (0)
- Chapter 2 – Cancer Screening and Prevention in the Older Patient (2012) (0)
- Cancer Overdiagnosis, Ramifications and Research Strategies (2017) (0)
- Misleading Statement in Trial on False-Positive Results in Lung Cancer Screening. Authors' reply (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Barnett S. Kramer?
Barnett S. Kramer is affiliated with the following schools:
